Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Moomoo 24/7Apr 23 08:55 ET
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Moomoo 24/7Apr 22 19:50 ET
Little Excitement Around Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues As Shares Take 27% Pounding
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shareholders won't be pleased to see that the share price has had a very rough month, dropping 27% and undoing the prior period's positive performance. Fo
Simply Wall StApr 21 08:00 ET
Pieris Pharmaceuticals To Carry Out 1-for-80 Reverse Stock Split On April 23rd, 2024
April 20th - $Pieris Pharmaceuticals(PIRS.US)$ is about to implement a 1-for-80 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 23rd, 2024.$Pieris Pha
moomoo NewsApr 19 19:40 ET
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value
AccesswireApr 19 12:10 ET
Express News | Pieris Pharmaceuticals Inc: Common Stock Trading on a Reverse Split-Adjusted Basis Will Begin at Market Open on Tuesday, April 23, 2024.
Moomoo 24/7Apr 18 16:24 ET
Express News | Pieris Pharmaceuticals- Announces 1-for-80 Reverse Stock Split
Moomoo 24/7Apr 18 16:23 ET
Pieris Pharmaceuticals Announces Repositioning Plan To Optimize Potential Milestones And Royalties Including Discontinuation Of R&D Efforts And Workforce Reduction
Pieris Pharmaceuticals Announces Repositioning Plan To Optimize Potential Milestones And Royalties Including Discontinuation Of R&D Efforts And Workforce Reduction
BenzingaMar 27 08:06 ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersEtao International Co (NASDAQ:ETAO) shares increased by 180.5% to $0.4 during Wednesday's pre-market session. The company's market cap stands at $40.4 million. Jaguar Health (NASDAQ:JAGX) stock
BenzingaMar 20 09:05 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersGeron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion. Madrigal Pharmaceuticals (NASDAQ:M
BenzingaMar 14 17:33 ET
Prime Medicine Names Foghorn Therapeutics' CFO to Be Its New Finance Chief
Prime Medicine (PRME) said Friday it has selected a new chief financial officer, with Allan Reine slated to join the biotechnology genetic therapies company on Jan. 17. Reine joins the company from hi
MT NewswiresJan 5 10:41 ET
Investors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%
Yahoo FinanceDec 18, 2023 05:23 ET
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
Zacks Sep 25, 2023 00:00 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersYS Biopharma Co (NASDAQ:YS) shares moved upwards by 72.0% to $1.34 during Friday's pre-market session. The company's market cap stands at $124.6 million. Longeveron Inc. - Subscription Right (N
BenzingaAug 25, 2023 09:06 ET
Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis
Yahoo FinanceAug 24, 2023 12:32 ET
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
Yahoo FinanceAug 23, 2023 12:00 ET
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals
Pieris Pharmaceuticals (PIRS) said Thursday the dosing of the first patient in a phase 1/2 trial of cancer drug candidate BOS-342 triggered a milestone payment from Boston Pharmaceuticals. The study w
MT NewswiresAug 17, 2023 09:16 ET
Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Form
BenzingaAug 17, 2023 08:12 ET
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals.
AccesswireAug 17, 2023 08:01 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersModular Medical (NASDAQ:MODD) stock rose 33.3% to $1.36 during Wednesday's after-market session. Trading volume for this security closed at 1.4 million, accounting for 2289.8% of its average fu
BenzingaAug 16, 2023 17:32 ET
No Data
No Data